These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 7599121

  • 1. Correlation of antiviral activity with beta-turn types for V3 synthetic multibranched peptides from HIV-1 gp120.
    Mabrouk K, Van Rietschoten J, Rochat H, Loret EP.
    Biochemistry; 1995 Jul 04; 34(26):8294-8. PubMed ID: 7599121
    [Abstract] [Full Text] [Related]

  • 2. SPC3, a synthetic peptide derived from the V3 domain of human immunodeficiency virus type 1 (HIV-1) gp120, inhibits HIV-1 entry into CD4+ and CD4- cells by two distinct mechanisms.
    Yahi N, Fantini J, Baghdiguian S, Mabrouk K, Tamalet C, Rochat H, Van Rietschoten J, Sabatier JM.
    Proc Natl Acad Sci U S A; 1995 May 23; 92(11):4867-71. PubMed ID: 7761414
    [Abstract] [Full Text] [Related]

  • 3. SPC3, a V3 loop-derived synthetic peptide inhibitor of HIV-1 infection, binds to cell surface glycosphingolipids.
    Delézay O, Hammache D, Fantini J, Yahi N.
    Biochemistry; 1996 Dec 10; 35(49):15663-71. PubMed ID: 8961929
    [Abstract] [Full Text] [Related]

  • 4. V3 loop-derived peptide SPC3 inhibits infection of CD4- and galactosylceramide- cells by LAV-2/B.
    Moulard M, Mabrouk K, Martin I, Van Rietschoten J, Rochat H, Sabatier JM.
    J Pept Res; 1999 Jun 10; 53(6):647-55. PubMed ID: 10408339
    [Abstract] [Full Text] [Related]

  • 5. Ion channel activation by SPC3, a peptide derived from the HIV-1 gp120 V3 loop.
    Carlier E, Mabrouk K, Moulard M, Fajloun Z, Rochat H, De Waard M, Sabatier JM.
    J Pept Res; 2000 Dec 10; 56(6):427-37. PubMed ID: 11152302
    [Abstract] [Full Text] [Related]

  • 6. Multibranched peptide constructs derived from the V3 loop of envelope glycoprotein gp120 inhibit human immunodeficiency virus type 1 infection through interaction with CD4.
    Benjouad A, Chapuis F, Fenouillet E, Gluckman JC.
    Virology; 1995 Jan 10; 206(1):457-64. PubMed ID: 7831801
    [Abstract] [Full Text] [Related]

  • 7. Properties of HIV envelope expressed in the presence of SPC3, an Env-derived peptide drug under phase II clinical trials.
    Barbouche R, Fenouillet E, Papandréou MJ, Kiény MP, Sabatier JM.
    J Pept Res; 1998 Oct 10; 52(4):283-8. PubMed ID: 9832306
    [Abstract] [Full Text] [Related]

  • 8. Multibranched V3 peptides inhibit human immunodeficiency virus infection in human lymphocytes and macrophages.
    Yahi N, Fantini J, Mabrouk K, Tamalet C, de Micco P, van Rietschoten J, Rochat H, Sabatier JM.
    J Virol; 1994 Sep 10; 68(9):5714-20. PubMed ID: 8057453
    [Abstract] [Full Text] [Related]

  • 9. SPC3, a nontoxic peptide inhibitor of HIV infection.
    Sabatier JM, Baghdiguian S, Yahi N, Rochat H, Van Rietschoten J, Fantini J.
    In Vitro Cell Dev Biol Anim; 1995 Jun 10; 31(6):415-8. PubMed ID: 8589880
    [No Abstract] [Full Text] [Related]

  • 10. Liposomal encapsulation enhances antiviral efficacy of SPC3 against human immunodeficiency virus type-1 infection in human lymphocytes.
    de Mareuil J, Mabrouk K, Doria E, Moulard M, de Chasteigner S, Oughideni R, van Rietschoten J, Rochat H, De Waard M, Sabatier JM.
    Antiviral Res; 2002 Jun 10; 54(3):175-88. PubMed ID: 12062390
    [Abstract] [Full Text] [Related]

  • 11. Synthesis and conformational studies of N-glycosylated analogues of the HIV-1 principal neutralizing determinant.
    Laczkó I, Hollósi M, Urge L, Ugen KE, Weiner DB, Mantsch HH, Thurin J, Otvös L.
    Biochemistry; 1992 May 05; 31(17):4282-8. PubMed ID: 1567873
    [Abstract] [Full Text] [Related]

  • 12. SPC3, an anti-HIV peptide construct derived from the viral envelope, binds and enters HIV target cells.
    Barbouche R, Miquelis R, Sabatier JM, Fenouillet E.
    J Pept Sci; 1998 Dec 05; 4(8):479-85. PubMed ID: 9927254
    [Abstract] [Full Text] [Related]

  • 13. Conformational features of a synthetic cyclic peptide corresponding to the complete V3 loop of the RF HIV-1 strain in water and water/trifluoroethanol solutions.
    Vranken WF, Budesinsky M, Martins JC, Fant F, Boulez K, Gras-Masse H, Borremans FA.
    Eur J Biochem; 1996 Feb 15; 236(1):100-8. PubMed ID: 8617252
    [Abstract] [Full Text] [Related]

  • 14. Structural analysis of the HIV-1 gp120 V3 loop: application to the HIV-Haiti isolates.
    Andrianov AM, Veresov VG.
    J Biomol Struct Dyn; 2007 Jun 15; 24(6):597-608. PubMed ID: 17508782
    [Abstract] [Full Text] [Related]

  • 15. Structural requirements for and consequences of an antiviral porphyrin binding to the V3 loop of the human immunodeficiency virus (HIV-1) envelope glycoprotein gp120.
    Neurath AR, Strick N, Debnath AK.
    J Mol Recognit; 1995 Jun 15; 8(6):345-57. PubMed ID: 9052975
    [Abstract] [Full Text] [Related]

  • 16. Recognition properties of V3-specific antibodies to V3 loop peptides derived from HIV-1 gp120 presented in multiple conformations.
    Huisman JG, Carotenuto A, Labrijn AF, Papavoine CH, Laman JD, Schellekens MM, Koppelman MH, Hilbers CW.
    Biochemistry; 2000 Sep 05; 39(35):10866-76. PubMed ID: 10978173
    [Abstract] [Full Text] [Related]

  • 17. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.
    Wild C, Oas T, McDanal C, Bolognesi D, Matthews T.
    Proc Natl Acad Sci U S A; 1992 Nov 01; 89(21):10537-41. PubMed ID: 1438243
    [Abstract] [Full Text] [Related]

  • 18. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
    Borbe HC, Stuber G, Wagner R, Wolf H, Modrow S.
    J Pept Sci; 1995 Nov 01; 1(2):109-23. PubMed ID: 9222988
    [Abstract] [Full Text] [Related]

  • 19. HIV type 1 V3 peptide constructs act differently on HIV type 1 infection of peripheral blood lymphocytes and macrophages.
    Benjouad A, Seddiki N, Ylisastigui L, Gluckman JC.
    AIDS Res Hum Retroviruses; 1997 Feb 10; 13(3):219-26. PubMed ID: 9115808
    [Abstract] [Full Text] [Related]

  • 20. NMR and circular dichroism studies on the conformation of a 44-mer peptide from a CD4-binding domain of human immunodeficiency virus envelope glycoprotein.
    Chang DK, Chien WJ, Cheng SF, Chen ST.
    J Pept Res; 1997 May 10; 49(5):432-43. PubMed ID: 9211225
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.